CelluTarget · Multifocal Motor Neuropathy · Treatments
◦ Stalled Program

ANX005 (announced, no active registered trial)

Annexon, Inc. ↗
2
Evidence entries
1
Clinical trials
Overview
Treatment Details
Mechanism of Action
Monoclonal antibody targeting complement C1q. Company announced intent (2021, reaffirmed 2023) to advance into Phase 2 for MMN, but subsequent company communications (2025) list flagship programs (GBS, Huntington's disease, geographic atrophy, ANX1502) without MMN, and no MMN trial has been found registered on ClinicalTrials.gov. Included as a documented but apparently stalled/deprioritized program.
Dosing Notes
N/A — no active MMN trial identified.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only
Company announced intent to move ANX005 into Phase 2 for MMN (2021, reaffirmed 2023).
Verified Jul 2026
Institutional ResearchSuperseded
Annexon announces plan to advance ANX005 into Phase 2 program in MMN
Published July 2021
View source ↗
2025 company outlook lists flagship programs without MMN; no registered MMN trial found — program appears stalled or deprioritized.
Verified Jul 2026
Institutional Research
Annexon 2025 outlook — flagship programs (GBS, HD, GA, ANX1502); MMN not listed
Published January 2025
View source ↗
Clinical Trials
Linked Trials1 trial
No registry ID — unregistered program
No registered trial found — program announced 2021/2023, absent from 2025 flagship program list
N/A
Unknown